Enhanced anti-tumor effect of combination therapy with anti-CD40 antibody and the mTOR kinase inhibitor AZD8055

被引：0
|
作者：
Jiang, Qun
Weiss, Jonathan M.
Ortaldo, John R.
Back, Timothy
Guichard, Sylvie
Thakurta, Anjan
Wiltrout, Robert H.
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-5596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5596
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Enhanced Anti-tumor Effect of Combination Therapy With Anti-CD40 Antibody and the mTOR Kinase Inhibitor AZD8055
    Jiang, Qun
    Weiss, Jonathan M.
    Ortaldo, John R.
    Back, Timothy
    Guichard, Sylvie
    Thakurta, Anjan
    Wiltrout, Robert H.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 898 - 898
  • [2] mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
    Jiang, Qun
    Weiss, Jonathan M.
    Back, Timothy
    Chan, Tim
    Ortaldo, John R.
    Guichard, Sylvie
    Wiltrout, Robert H.
    CANCER RESEARCH, 2011, 71 (12) : 4074 - 4084
  • [3] Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo
    Xu, Dong-Qing
    Toyoda, Hidemi
    Yuan, Xiao-Jun
    Qi, Lei
    Chelakkot, Vipin Shankar
    Morimoto, Man
    Hanaki, Ryo
    Kihira, Kentarou
    Hori, Hiroki
    Komada, Yoshihiro
    Hirayama, Masahiro
    EXPERIMENTAL CELL RESEARCH, 2018, 365 (02) : 177 - 184
  • [4] Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
    Holt, Sarah V.
    Logie, Armelle
    Davies, Barry R.
    Alferez, Denis
    Runswick, Sarah
    Fenton, Sarah
    Chresta, Christine M.
    Gu, Yi
    Zhang, Jingchuan
    Wu, Yi-Long
    Wilkinson, Robert W.
    Guichard, Sylvie M.
    Smith, Paul D.
    CANCER RESEARCH, 2012, 72 (07) : 1804 - 1813
  • [5] Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages
    Hu, Weimin
    Zhang, Yunlong
    Ning, Jinzhuo
    Li, Ming
    Tang, Yuqi
    Li, Linzhi
    Cheng, Fan
    Yu, Weimin
    HELIYON, 2023, 9 (03)
  • [6] A humanized anti-cd40 antibody with anti-tumor pharmacological activity and cynomolgus monkey safety
    Li, Zhenyu
    Zhao, Lili
    Zhang, Guimin
    Li, Bin
    Liu, Zhong
    Li, Guangyan
    Zhu, Zhongsong
    CANCER RESEARCH, 2023, 83 (07)
  • [7] The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
    Willems, L.
    Chapuis, N.
    Puissant, A.
    Maciel, T. T.
    Green, A. S.
    Jacque, N.
    Vignon, C.
    Park, S.
    Guichard, S.
    Herault, O.
    Fricot, A.
    Hermine, O.
    Moura, I. C.
    Auberger, P.
    Ifrah, N.
    Dreyfus, F.
    Bonnet, D.
    Lacombe, C.
    Mayeux, P.
    Bouscary, D.
    Tamburini, J.
    LEUKEMIA, 2012, 26 (06) : 1195 - 1202
  • [8] Enhanced T Cell-Independent Anti-tumor Effect of Cyclophosphamide Combined With Anti-CD40 MAB and CpG
    Johnson, Erik E.
    Buhtoiarov, Ilia N.
    Waisbren, Julie B.
    Sondel, Paul M.
    Rakhmilevich, Alexander L.
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 954 - 954
  • [9] The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
    L Willems
    N Chapuis
    A Puissant
    T T Maciel
    A S Green
    N Jacque
    C Vignon
    S Park
    S Guichard
    O Herault
    A Fricot
    O Hermine
    I C Moura
    P Auberger
    N Ifrah
    F Dreyfus
    D Bonnet
    C Lacombe
    P Mayeux
    D Bouscary
    J Tamburini
    Leukemia, 2012, 26 : 1195 - 1202
  • [10] Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy
    Baumann, Daniel
    Offringa, Rienk
    CELL STRESS, 2020, 4 (10) : 248 - 251
12345